ERG and prostate carcinoma: While the TMPRSS2:ETV1 fusion is rare and occurs in 1–10% of prostate cancers [75], the TMPRSS2:ERG fusion is present in roughly half of prostate cancers and is the most common genetic aberration so far described in prostate cancer.